Citigroup Issues Positive Forecast for BioAge Labs (NASDAQ:BIOA) Stock Price

BioAge Labs (NASDAQ:BIOA) had its target price boosted by Citigroup from $15.00 to $52.00 in a report released on Tuesday morning,Benzinga reports. Citigroup currently has a buy rating on the stock.

BIOA has been the topic of a number of other reports. Morgan Stanley set a $23.00 price target on shares of BioAge Labs in a research report on Wednesday, February 4th. Oppenheimer began coverage on shares of BioAge Labs in a research report on Wednesday, February 25th. They set an “outperform” rating and a $60.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a report on Tuesday, January 27th. Piper Sandler began coverage on shares of BioAge Labs in a research report on Tuesday, January 27th. They issued an “overweight” rating for the company. Finally, Wall Street Zen upgraded BioAge Labs from a “sell” rating to a “hold” rating in a research note on Tuesday, February 3rd. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $45.00.

BioAge Labs Stock Performance

Shares of BioAge Labs stock opened at $20.97 on Tuesday. The firm has a 50-day moving average of $19.26 and a 200-day moving average of $11.79. The stock has a market cap of $751.77 million, a PE ratio of -13.80 and a beta of 1.22. BioAge Labs has a 52-week low of $2.88 and a 52-week high of $24.00.

Insider Activity at BioAge Labs

In related news, insider Paul D. Rubin sold 7,433 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $18.75, for a total transaction of $139,368.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Kristen Fortney sold 233,107 shares of the stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $18.12, for a total transaction of $4,223,898.84. Following the sale, the chief executive officer owned 976,949 shares in the company, valued at $17,702,315.88. The trade was a 19.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 267,540 shares of company stock valued at $4,895,168 over the last quarter. 20.82% of the stock is owned by corporate insiders.

Institutional Trading of BioAge Labs

Several large investors have recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in BioAge Labs by 60.8% in the second quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock valued at $1,873,000 after acquiring an additional 171,426 shares during the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new position in BioAge Labs during the second quarter valued at approximately $27,000. Intech Investment Management LLC bought a new stake in BioAge Labs during the second quarter worth $60,000. Jefferies Financial Group Inc. bought a new stake in BioAge Labs during the second quarter worth $206,000. Finally, Stonepine Capital Management LLC boosted its holdings in shares of BioAge Labs by 202.2% in the 2nd quarter. Stonepine Capital Management LLC now owns 151,085 shares of the company’s stock valued at $624,000 after purchasing an additional 101,085 shares in the last quarter.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.